RxDoctor Payments Data

Kaitlin Schwerer, DO

Family Medicine · Milan, OHNPI 1659767812

Payments from drug & device makers

$5,790in general payments, 2019–2025

Across 349 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$602
  • AstraZeneca$515
  • Pfizer$430
  • Lilly USA, LLC$430
  • Abbott$225
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,790100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,790 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$53,165
Medicare patients
247
Services billed
933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$79,013
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$73,817
MounjaroTirzepatide49$66,679
EliquisApixaban45$58,317
TrulicityDulaglutide33$56,206
JanuviaSitagliptin Phosphate39$51,931
JardianceEmpagliflozin25$42,962
FarxigaDapagliflozin Propanediol36$39,375
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$24,033
Tresiba Flextouch U-100Insulin Degludec19$17,919
XareltoRivaroxaban16$17,679
MyrbetriqMirabegron18$17,601
RexultiBrexpiprazole11$15,907
Advair HfaFluticasone Propion/Salmeterol15$8,623
Potassium Chloride225$8,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$430$122,88582 claims
GSKTrelegy Ellipta, Anoro Ellipta$173$97,85186 claims
Novo NordiskOzempic$602$79,01353 claims
PfizerEliquis, Paxlovid$430$61,04056 claims
MerckJanuvia$107$51,93139 claims
Boehringer IngelheimJardiance$136$42,96225 claims
AstraZenecaFarxiga$515$39,37536 claims
Johnson & JohnsonXarelto$29$17,67916 claims
Astellas Pharma US IncMyrbetriq$132$17,60118 claims
Otsuka America Pharmaceutical, Inc.Rexulti$49$15,90711 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$3,241266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Milan

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →